The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Mutlu HizalBurak BilginNail PaksoyMuhammed Mustafa AtcıSeda KahramanSaadettin KılıçkapDeniz Can GüvenMerve KeskinkılıçMurat AyhanÖnder ErenFatma Nihan Akkoç MustafayevŞebnem YamanErtuğrul Bayramİsmail ErtürkErkan ÖzcanMustafa KorkmazBaran AkagündüzDilek ErdemTuğba Akın TelliAsude AksoyNecdet ÜskentNaziyet Köse BaytemürAhmet GülmezDinçer AydınTeoman ŞakalarHacı ArakAli Murat TatlıYakup ErgünNaziye AkÇağlar ÜnalMehmet Alpaslan ÖzgünBülent Yalçınİlhan ÖztopEfnan AlgınAbdullah SakinAdnan AydınerPerran Fulden YumukMehmet Ali Nahit ŞendurPublished in: Journal of cancer research and clinical oncology (2022)
Our study demonstrated that the efficacy of alectinib varies significantly across patient subgroups with different percentages of ALK-positive cells. If these findings are prospectively validated, the percentage of ALK-positive cells may be used as a stratification factor in randomized trials comparing different ALK-TKIs.